According to study details released Friday as the U.S. considers opening vaccinations to that age group, kid-size doses of Pfizer's COVID-19 vaccine appear safe and nearly 91per cent effective at preventing symptomatic infections in 5- to 11-year-olds.
The shots could begin in early November with
A booster dose of the COVID-19 vaccine developed by Pfizer Inc (PFE.N) and German partner BioNTech SE (22UAy.DE) was 95.6% effective against the coronavirus when compared to a vaccinated group that did not get the third shot, data from a large study released by the companies showed on Thursday.
A study run by the National Institutes of Health showed on Wednesday that people who got Johnson & Johnson Inc’s (JNJ.N) COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer Inc (PFE.N)/BioNTech SE or Moderna Inc (MRNA.O).
The study, which is preliminary
On Monday, World Health Organization recommended that immunocompromised people be given an additional dose of COVID-19 vaccine, due to their higher risk of breakthrough infections after standard immunisation.
The Strategic Advisory Group of Experts on immunization said that the additional dose should be offered "as part
Zydus Cadila's Covid-19 vaccine may cost around Rs 300 per dose, people in the know told ET. As government inches closer to deciding the price of vaccine which is likely to be introduced in the vaccination drive this month, people who are part of discussions said that "the
In England, all 12- to 15-year-olds will be offered a COVID-19 vaccine after the top medical advisers said on Monday that this will benefit children from reduced disruption to their education.
The British government confirmed that the offer would be extended to all children aged 12-15
According to an official statement on Friday, India has granted homegrown drugmaker Biological E permission to begin midtage studies of its COVID-19 vaccine in children and adolescents.
The Drugs Controller General of India (DCGI) gave the approval to the Hyderabad-based pharmaceutical company on Sept. 1, the statement said.
According to the sources, The DCGI (The Drugs Controller General of India) granted permission to Mukesh Ambani-owned Reliance Life Sciences to conduct its COVID-19 vaccine trial on friday with certain conditions. The safety, tolerability and immunogenicity of the SARS-CoV-2 recombinant protein subunit vaccine in healthy
Johnson & Johnson (J&J) on Friday said it has submitted an application to the Indian drug regulator to conduct a study of its Covid-19 vaccine in adolescents aged 12-17 years. The US-based pharmaceutical company noted that it is committed to facilitating global equitable access to
On Monday the Government made an announcement to the effect that foreigners who are living in India are eligible to receive Covid-19 vaccination in this country. They can register on the CoWin platform, and the only document required is their passport. “This is a landmark